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a b s t r a c t 
Tissue factor pathway inhibitor-2 (TFPI-2) is a potent inhibitor of plasmin, a protease which is involved
in tumour progression by activating (MMPs). This therefore makes TFPI-2 a potential inhibitor of inva-
siveness and the development of metastases. In this study, low levels of TFPI-2 expression were found
in 65% of patients with small cell lung cancer (SCLC), the most aggressive type of lung cancer. To study
the impact of TFPI-2 in tumour progression, TFPI-2 was overexpressed in NCI-H209 SCLC cells which
were orthotopically implanted in nude mice. Investigations showed that TFPI-2 inhibited lung tumour
growth. Such inhibition could be explained in vitro by a decrease in tumour cell viability, blockade
of G1 / S phase cell cycle transition and an increase in apoptosis shown in NCI-H209 cells expressing
TFPI-2. We also demonstrated that TFPI-2 upregulation in NCI-H209 cells decreased MMP expression,
particularly by downregulating MMP-1 and MMP-3. Moreover, TFPI-2 inhibited phosphorylation of the
MAPK signalling pathway proteins involved in the induction of MMP transcripts, among which MMP-1
was predominant in SCLC tissues and was inversely expressed with TFPI-2 in 35% of cases. These results
suggest that downregulation of TFPI-2 expression could favour the development of SCLC. 
C © 2013 The Authors. Published by Elsevier B.V. on behalf of Federation of European Biochemical
Societies. Open access under CC BY-NC-ND license. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 1. Introduction 
Lung cancer remains the main cause of cancer deaths worldwide
[ 1 ] and new targeted molecular therapies are currently being devel-
oped. Small cell lung cancer (SCLC) is the most common neuroen-
docrine tumour of the lung (15% of cases) [ 2 , 3 ] and is strongly as-
sociated with smoking [ 4 ]. It is characterised by tumours that grow
rapidly with early metastases to the bones, brain, liver and adrenal
glands and therefore a limited number of patients are diagnosed at a* Corresponding author. Address: Centre d ’ Etude des Pathologies Respiratoires, In- 
serm U1100 / EA 6305, Facult ´e de M ´edecine, 10 Boulevard Tonnell ´e, 37032 Tours Cedex, 
France. Tel.: + 33 2 47 36 60 67; fax: + 33 2 47 36 60 46. 
E-mail address: reverdiau@med.univ-tours.fr (P. Reverdiau). 
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http://dx.doi.org/10.1016/j.fob.2013.06.004 local stage. The 5-year survival rate for patients with SCLC is only 2%
in advanced stages and 25% for localised disease [ 5 ]. Less than 10% of
patients with SCLC have a resectable tumour, thus surgical specimens
are scarce and most tumour samples come from small biopsies ob-
tained during bronchial endoscopy or mediastinoscopy, which allow
diagnosis but do not allow extensive ancillary studies. 
Several mechanisms, including degradation of the extracellular
matrix (ECM), are involved in the spread of cancer cells from the pri-
mary tumour. Among the variety of proteinases acting in proliferation
and invasion processes, serine proteinases [ 6 ] and matrix metallopro-
teinases (MMPs) have been shown to be highly expressed and acti-
vated in the tumour microenvironment [ 7 ], especially in highly ag-
gressive malignant tumours [ 8 ]. One potent inhibitor of proteinases
is tissue factor pathway inhibitor-2 (TFPI-2), a 32 kDa Kunitz-type
serine proteinase inhibitor secreted within the ECM and now con-
sidered to be a candidate tumour suppressor gene. In particular, it
inhibits plasmin which is involved in MMP activation and could thus
regulate ECM degradation and tumour cell invasion. Unfortunately,ean Biochemical Societies. Open access under CC BY-NC-ND license.
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fFPI-2 is downregulated in most aggressive tumours such as glioma 
 9 ], non-small cell lung cancer (NSCLC) [ 10 , 11 ], breast cancer [ 12 ],
elanoma [ 13 ], colorectal cancer [ 14 ], pancreatic cancer [ 15 ] and 
epatocellular carcinoma [ 16 ]. Such silencing is mainly due to epi- 
enetic changes induced by TFPI-2 promoter hypermethylation and 
istone deacetylation [ 12 , 17 , 18 , 19 ]. Aberrant methylation of TFPI-2 
s now being studied to differentiate benign from malign diseases 
nd to evaluate disease progression [ 20 , 21 , 22 ]. Tumour cells are also 
ble to synthesize an untranslated splice variant of TFPI-2 transcript 
hat correlates with a low level of full-length TFPI-2 transcript [ 23 ]. 
he micro RNA-616 targeting TFPI-2 3 ’ UTR was recently observed in 
rostate cancer and was found to be inversely correlated with TFPI-2 
xpression [ 24 ]. Moreover, TFPI-2 transcription could be regulated 
y polymorphisms in the promoter sequence affecting transcription 
actor binding sites [ 25 ]. Absence of TFPI-2 expression can also occur 
hrough deletion of the chromosomal region 7q22, as in prostate can- 
er [ 26 ]. We have previously shown that the decrease in TFPI-2 and 
ypermethylation of its gene promoter in lung cancer were associated 
ith advanced stages of NSCLC, particularly in cases with lymph node 
etastases [ 10 ]. Moreover, methylation of TFPI-2 was also found to 
e an independent prognostic factor for poor overall survival in pa- 
ients with NSCLC [ 11 ]. More generally, absence or low expression 
f TFPI-2 in many cancer cells, including lung cancer cells, has been 
orrelated with increase in their invasive potential [ 27 , 28 , 29 ]. In con- 
rast, induction of TFPI-2 expression using stable transfection or a 
ecombinant adenovirus has been shown to decrease the invasive- 
ess of cancer cells such as prostate cancer cells [ 30 ], glioblastoma 
ells [ 31 ], oesophageal carcinoma cells [ 32 ] and pancreatic carcinoma 
ells [ 33 ]. No study has yet demonstrated the beneﬁcial role of TFPI-2 
estoration in lung cancer, particularly in SCLC. 
We therefore investigated TFPI-2 expression in tissue samples 
rom patients with SCLC and evaluated the impact of TFPI-2 restora- 
ion in the NCI-H209 cell line on tumour growth in a mouse orthotopic 
odel. In order to explain the role of TFPI-2 in tumour progression, 
e compared proliferation, cell cycle, apoptosis and MMP expres- 
ion in NCI-H209 cells expressing TFPI-2 and those without. Finally, 
e compared immunostaining scores of TFPI-2 and MMP on human 
CLC biopsy specimens to evaluate whether downregulation of TFPI-2 
ight be involved in the aggressiveness of SCLC. 
. Materials and methods 
.1. Human tumour tissue samples 
Cases of SCLC were gathered from the ﬁles of the Pathology De- 
artment of CHRU Tours (France) between February 2004 and March 
007. Tumour diagnosis was performed on biopsy specimens ob- 
ained by bronchoscopy ( n = 33) or mediastinoscopy ( n = 7) ﬁxed in 
ormalin and parafﬁn embedded. A total of 40 patients met the follow- 
ng inclusion criteria: histologically conﬁrmed diagnosis of primary 
CLC fulﬁlling the 2004 World Health Organization (WHO) classiﬁca- 
ion criteria, adequate clinical data recorded, tissue specimen avail- 
ble for additional immunohistological assay. The medical records 
ere reviewed to collect the following data: age at diagnosis, sex, 
moking history, relevant comorbidities, tumour stage and metas- 
ases, date of last consultation or death. Haematoxylin–eosin–safran 
HES) and immunohistochemically stained slides were re-examined 
o conﬁrm the diagnosis according the 2004 the WHO classiﬁcation of 
ung tumours. Frozen ( −80 ◦C) tumour material was available for 5 pa- 
ients who had had a mediastinoscopy. Staging was assessed accord- 
ng to the Veterans ’ Administration Lung Study Group (VALSG) as rec- 
mmended by 2004 WHO classiﬁcation. A statement of ‘no objection ’ 
as obtained for each patient by complying with French legislation 
or research. 2.2. Antibodies 
The polyclonal rabbit anti-TFPI-2 antibodies were the generous gift 
of W. Kisiel. Monoclonal rabbit anti-MMP-1 and monoclonal goat anti- 
MMP-3 antibodies were purchased from R&D systems (Lille, France). 
Polyclonal rabbit IgG antibody anti-phospho-ERK1 / 2 and anti-ERK1 / 2 
were purchased from Calbiochem. Monoclonal anti β-actin mouse IgG 
was from Sigma–Aldrich (Saint-Quentin Fallavier, France). For these 
antibodies we used peroxidase-labelled anti-mouse IgG (Sigma–
Aldrich), peroxidase-labelled anti-goat IgG and anti-rabbit IgG (Santa 
Cruz, TEBU, Le Perray en Yvelines, France). Monoclonal rabbit IgG an- 
tibody against cleaved caspase 3 (Asp175, 5A1E clone), cleaved cas- 
pase 9 (Asp330), phospho cRaf (Ser338, 56A6 clone), phospho MEK1 / 2 
(Ser217 / 221, 41G9 clone) and phospho GSK-3 β (Ser9, 5B3 clone) were 
purchased from Cell Signaling (Ozyme, Saint Quentin en Yvelines, 
France). Monoclonal mouse IgG1 anti-CDK4 antibody (DCS156 clone), 
polyclonal rabbit IgG anti-p15 INK4B and anti-p27 Kip1 antibodies were 
also from Cell Signaling. The secondary antibodies were peroxidase- 
labelled anti-rabbit IgG and peroxidase-labelled anti-mouse IgG from 
Cell Signaling. Polyclonal rabbit antibody anti-chromogranin A, mon- 
oclonal mouse IgG2 against EMA (clone E29) and IgG1 against cytok- 
eratin (clone KL1) or synaptophysin (clone SY38) were from Dako 
(Trappes, France). Mouse monoclonal IgG1 anti-CD56 (clone 1B6) 
was purchased from Novocastra (Leica Microsyst `emes SAS, Nanterre, 
France). Rabbit polyclonal antibodies against MMP-1 and MMP-9, 
mouse monoclonal IgG1 antibody against MMP-2 (clone A-Gel VC2) 
and mouse mAb IgG2b against MMP-3 (clone SL-1IID4) were pur- 
chased from LabVision Corporation (Thermo Scientiﬁc, St Leon-Rot, 
Germany). 
2.3. Cell culture and transfection 
The NCI-H209 cell line derived from SCLC was obtained from 
the ATCC (LGC Promochem, Molsheim, France). Floating aggregate 
cells were grown in RPMI-1640 medium (Invitrogen, Cergy Pontoise, 
France) supplemented with 2 mM l -glutamine, 100 IU / mL penicillin, 
100 μg / mL streptomycin and 10% endotoxin-free heat-inactivated 
foetal calf serum (FCS) (Lonza, Basel, Switzerland) at 37 ◦C in a hu- 
midiﬁed atmosphere with 5% CO 2 . Cells were then transfected with 4 
μg of pCMV-luc plasmid (Clontech, Saint Quentin en Yvelines, France) 
using 10 μg Lipofectamine 2000 reagent according to the manufac- 
turer’s instructions (Invitrogen) and as previously described [ 34 ]. Af- 
ter transfection, cells were selected in complete medium containing 
300 μg / mL G418, and stable clones expressing the highest levels of 
luciferase (NCI-H209 Luc cells) were isolated and cultured with 50 
μg / mL G418 (Invitrogen). 
To enhance the tumourigenicity of the NCI-H209 clone selected, 
two passages were performed in vivo . Animals were anaesthetised 
with 100 mg / kg Ketamine 1000 (Virbac, Wissour, France) and 15 mg / 
kg Rompun 2% (Bayer Sant ´e, Puteaux, France). NCI-H209 Luc cells 
(2.5 × 10 6 ) in 250 μL of FCS-free RPMI medium containing 4 mg / 
mL Matrigel 
TM 
(Becton Dickinson, Le Pont de Claix, France) were in- 
jected into the scapula. Animals were sacriﬁced after 25 days and 
the subcutaneous tumours were harvested aseptically, minced into 
small fragments that were then gently dissociated in the medium. 
Cells were then cultured in complete medium containing 50 μg / mL 
G418 until further subcutaneous implantation or transfection. 
NCI-H209 Luc cells were transfected with 4 μg of pEF6 / V5-His- 
TOPO plasmid (Invitrogen) containing the TFPI-2 cDNA or only with 
the plasmid using 10 μg Lipofectamine 2000 reagent (Invitrogen). Six 
hours after transfection, the medium was replaced by fresh complete 
medium containing 10% FCS. After 24 h, cells were cultured in 6-well 
plates with selection medium containing 2 μg / mL blasticidin (In- 
vivoGen, Toulouse, France). Successfully transfected cell clones were 
then obtained by 3-weeks ’ culture in the selection medium, and the 
clones expressing the highest levels of TFPI-2 were selected. TFPI-2 
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Table 1 
Oligonucleotide sequences used for qPCR. 
Gene Sequences (5 ′ 3 ′ ) 
TFPI-2 Forward: AACGCCAACAATTTCTACACCT 
Reverse: TACTTTTCTGTGGACCCCTCAC 
MMP-1 Forward: CTGCTGCTGTTCTGGGGT 
Reverse: GCCACTATTTCTCCGCTTTTC 
MMP-2 Forward: GGCCCTGTCACTCCTGAGAT 
Reverse: CAGTCCGCCAAATGAACCGG 
MMP-3 Forward: ATCCCGAAGTGGAGGAAAAC 
Reverse: GCCTGGAGAATGTGAGTGGA 
MMP-9 Forward: AGACCGGTGAGCTGGATAG 
Reverse: GTGATGTTGTGGTGGTGCC 
β-Actin Forward: GCCCTAGACTTCGAGCAAGA 
Reverse: AGGAAGGAAGGCTGAAGAG 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 expression was assessed by reverse transcriptase and real-time PCR,
Western blotting and immunohistochemical staining. 
2.4. Nude mouse orthotopic model of human SCLC 
Four-week-old pathogen-free male BALB / c nude mice (Charles
River laboratories, Lyon, France) were acclimatised for 2 weeks in
a sterile environment before starting the study. All animals were
handled and cared for in accordance with National and Institu-
tional guidelines. Protocols were conducted under the supervision
of an authorised investigator with the approval of the Institution’s
Ethics Committee where experiments were performed (CIPA, TAAM-
UPS44 Orl ´eans, France). Mice were maintained in sterilised ﬁlter-
stopped cages throughout the experiments. They were examined
daily and monitored for signs of distress, decreased physical activ-
ity and weight. 
Before implantation, NCI-H209 Luc cells were collected after cen-
trifugation (3 min, 200 g ) and washed twice in FCS-free medium, and
the Trypan Blue dye exclusion test was used to assess cell viability
> 95%. The intrabronchial tumour cell implantation procedure was
performed as previously described [ 34 ]. Mice were anaesthetised as
previously described and the surgery area prepared with skin disin-
fection using betadine swabs. Immediately before transplantation, a
99m Tc-labelled tin colloid used as tracer was added to the cell sus-
pension containing 4 mg / mL Matrigel 
TM 
(Becton Dickinson) and 10
mM EDTA. A 0.5 cm ventral incision was made over the upper re-
gion of the trachea to expose the trachea that was punctured using
a 23-gauge needle. Cell inoculum (2.5 × 10 6 tumour cells in 25 μL)
was aspirated in a 1.9 Fr x 50 cm blunt-ended catheter (Becton Dick-
inson) that was inserted and advanced preferentially into the right
main bronchus. The position of the catheter was monitored using high
resolution radiological imaging (MX-20, Faxitron X-ray Corporation,
Wheeling, USA). Tumour cells were slowly injected into the lung and
scintigraphic evaluation of cell deposition in the lung was performed
(Gamma Imager, Biospace Mesures, Paris, France). The catheter was
removed, the incision closed and the animals were placed on a heated
pad (37 ◦C) until fully awake. Animal reactions were observed to en-
sure recovery from the anaesthesia. 
2.5. Bioluminescence imaging 
Mice were injected with 100 mg / kg D-luciferin (Promega, Char-
bonni `eres, France) and anaesthetised with 2% vapourised isoﬂuorane
concentration 4 min later, just before the bioluminescence imaging
(BLI). Images were obtained with an IVIS Lumina (Caliper LS, Hop-
kinton MA, USA) generating a pseudocolour image representing light
intensity and superimposed over a greyscale reference image. A mean
integration time of 5 min was used for acquisition, and signal inten-
sity was quantiﬁed as the sum of all the photons detected from both
the ventral and dorsal positions within a region of interest positioned
over the lung (Living Image software, v.2.GO, Caliper LS). 
2.6. Computed tomography scanning 
Microcomputed tomography (CT) was performed on a small ani-
mal imager (eXplore Locus, General Electric, Fairﬁeld CT USA) to doc-
ument tumour location and measurement, mice being anaesthetised
with 1.5% isoﬂurane for the duration of the examination procedure.
Source parameters were 80 kV and 450 μA. A total of 360 views were
acquired with 1 ◦ angle of incrementation, an exposure time of 120 ms
and a resolution of 93 μm using external respiratory gating (Biovet,
USA). Widths (W, axial), heights (H, mid-sagittal), and lengths (L, mid-
sagittal) of tumours were measured and tumour volume was calcu-
lated using the ellipsoid formula 4 / 3 π (W / 2 × H / 2 × L / 2). Three
dimensional volume viewing of the lung tumour was performed with
eXplore Utilities software / eXplore Reconstruction Utility. 2.7. Sacriﬁce, organ removal and histopathology analysis 
Mice were sacriﬁced by cervical dislocation under anaesthesia.
After laparotomy, thoracic and visceral cavities were examined for the
presence of metastases, and the lungs and trachea, heart, liver, spleen
and brain were collected from each animal. All organs were ﬁxed in
10% buffered formalin, embedded in parafﬁn and 5- μm thick sections
were prepared and stained with HES using a standard procedure. 
2.8. Reverse transcription and quantitative polymerase chain reaction 
(qRT-PCR) 
Total mRNA was extracted from 10 6 cells using the Dynabeads
mRNA Direct Kit (Invitrogen) according to the manufacturer’s in-
structions. Total mRNA was then reverse transcribed for 1 h at 42
◦C in incubation buffer containing 200 μM of each deoxynucleotide
triphosphate, 5 μM oligo(dT) 20 , 24 units RNase inhibitor, and 20 units
of avian myeloblastosis virus reverse transcriptase (Roche Applied
Science, Meylan, France). 
The amounts of TFPI-2, MMP-1, -2, -3 and -9 transcripts within
cells were assessed by qPCR using the icycler iQ detection system
(Bio-Rad, Ivry sur Seine, France). PCR was performed in a total reaction
volume of 25 μl containing 2 μl cDNA obtained from mRNA of 2.10 4
cells, 2-fold dilution of Platinum Quantitative PCR SuperMix-UDG (In-
vitrogen), 0.24 μM of each primer (Eurogentec, Angers, France, Table
1 ) and a 50,000-fold dilution of Sybr Green solution (Roche Applied
Science). To study gene expression, PCR were initiated by decontam-
ination (50 ◦C for 2 min) and denaturation steps (95 ◦C for 2 min),
followed by n cycles ( Table 1 ) at 95 ◦C for 20 s and at hybridation
temperature for 40 s. The melting curve was analysed for each sam-
ple to check PCR speciﬁcity. β-Actin was used for normalisation of
the quantity of RNA, and the C T value was subtracted from that of the
target gene to obtain a C T value. The relative quantitative measure-
ment of mRNA synthesis was expressed in 2 | CT| . The results were
then reported to those obtained from a cDNA stock of 852 cells and
used as a reference in all experiments. 
2.9. Cell preparation, culture supernatant and extracellular matrix 
isolation 
Cells were centrifuged and formalin ﬁxed, and cytoblocks were
then prepared for immunohistochemistry analysis. The cytoblock
technique was performed with the Shandon kit according to the man-
ufacturer’s instructions (Shandon Inc., Pittsburgh, PA). We slightly
modiﬁed the technique by using only one cytocentrifugation step.
The cluster of cells formed was routinely processed and parafﬁn em-
bedded. Immunohistochemistry was applied to 4 parafﬁn sections of
each specimen. 
To prepare surpernatants, cells were grown in fresh medium sup-
plemented with 1% Nutridoma (Roche Applied Science) for 4 days and
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pere 80-fold concentrated (Microcon, Millipore, Molsheim, France). 
roteins from the extracellular matrix were solubilised in TNC buffer 
50 mM Tris–HCl pH 7.5, 0.15 M NaCl, 10 mM CaCl 2 and 0.05% Brij 
5) by agitation and ﬁnger ﬂicking for 3 min and then centrifuged at 
5,000 g for 5 min. Proteins from whole cell lysates were extracted 
nd solubilised in RIPA buffer (50 mM Tris–HCl pH 7.5, 0.15 M NaCl, 
 mM EDTA, 1% Igepal 
®
and 0.25% sodium deoxycholate) after agita- 
ion between 2 and 10 min incubations at 4 ◦C and centrifugation at 
5,000 g for 5 min. 
.10. Western blotting 
Total protein concentrations of culture supernatants, whole cell 
ysates and ECM were measured using the Bradford method (To- 
al Protein Kit, Sigma–Aldrich). Proteins (3 μg) were separated on 
2% sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS- 
AGE) and transferred onto a nitrocellulose membrane. Membranes 
ere then saturated for 1 h at room temperature in TNT buffer (10 mM 
ris–HCl and 150 mM NaCl pH 7.4, 0.1% Tween-20) 1% BSA (Bovine 
erum Albumin), incubated overnight at 4 ◦C with primary antibod- 
es diluted in TNT buffer with 1% BSA and for 1h with appropriate 
eroxidase-conjugated secondary antibodies after washing with TNT 
uffer. Following exposure to the Chemiluminescence Reagent Plus 
Perkin Elmer Biosystems, Courtaboeuf, France) for 1–10 min, mem- 
ranes were drained, wrapped in a plastic bag and exposed to autora- 
iography ﬁlm (Sigma–Aldrich) for 10 min in the dark. 
.11. Immunohistochemistry analysis 
Immunohistochemistry studies were performed on 4 μm 
ormalin-ﬁxed, parafﬁn-embedded tissue and cytoblock sections. 
rieﬂy tissue sections were deparafﬁnized, rehydratated and sub- 
ected to water bath heat antigen retrieval for 20 min in a citrate 
uffer (Target Retrieval Solution pH 6.0, Dako) for MMP-1, MMP-9, 
hromogranin A, synaptophysin, CD56, KL1, EMA and TFPI-2, and in 
n ethylenediamine tetraacetic acid buffer pH 9.0 (Target Retrieval 
olution pH 9.0, Dako) for MMP-2 and MMP-3. For all proteins of inter- 
st, immunostaining was performed with the Lab Vision Autostainer 
Lab Vision Corporation) using a labelled streptavidin-biotin immu- 
oenzymatic detection system with diaminobenzidine as chromogen 
UltraVision, Lab Vision Corporation). Slides were haematoxylin coun- 
erstained. A semi quantitative intensity scale ranging from 0 to 3 (nil 
 0, weak = 1, moderate = 2, strong = 3) was used taking into account 
oth nuclear and cytoplasmic staining. 
.12. Gelatin zymography 
MMP-2 and MMP-9 activity in conditioned media and whole 
ell lysates were determined by gelatin zymography using standard 
ethodology. Brieﬂy, serum-free conditioned and concentrated me- 
ia or 50 μg proteins were half-diluted in sample buffer and loaded 
nto 10% (v / v) sodium dodecyl sulfate (SDS) polyacrylamide gels con- 
aining 1 mg / ml gelatin (Prolabo, Fontenay-sous-Bois, France). Pro- 
92 kDa) and active MMP-9 (82 kDa) as well as pro- (72 kDa) and active 
MP-2 (62 kDa) were used as standards (R&D Systems, Lille, France). 
lectrophoresis was performed at 15 mA / gel constant current for 2 
. Gels were then incubated twice in 100 ml 2.5% (v / v) Triton X-100 
Merck-Eurolab, Fontenay-sous-Bois, France) for 15 min to remove 
DS. The Triton solution was then removed and replaced with 100 ml 
eveloping buffer (50 mM Tris–HCl, pH 7.5, 5 mM CaCl 2 , and 0.02% 
odium azide). After 16 h incubation at 37 ◦C, the gels were stained for 
 h in 30% ethanol, 10% acetic acid, and 0.1% Coomassie brilliant blue 
-350 (GE Healthcare, Life Technologies, Illkirch, France) and then 
estained in 45% ethanol and 10% acetic acid. Areas of gelatin diges- 
ion were visualised as nonstained regions of the gel, and gels were 
rocessed using a GelDoc XR imaging densitometer (Bio-Rad). The intensity of the bands was quantiﬁed using Multi-Analyst computer 
software (Bio-Rad). 
2.13. Proliferation assay 
Tumour cells (10 5 ) were seeded in 24-well plates and cultured in 
culture medium containing 10% FCS. After 1, 4, 7, 12 and 15 days of 
culture, 140 μL of MTS reagent composed of 3-(4,5-dimethylthiazol- 
2-yl)-5-(3-carboxymethoxyphenyl)-2H-tetrazolium and an electron 
coupling agent, phenazine ethosulphate (CellTiter 96 ® AQ ueous One 
Solution, Promega, Charbonni `eres les Bains, France), was added. Cells 
were incubated for 45 min at 37 ◦C in a humidiﬁed atmosphere con- 
taining 5% CO 2 and absorbance was then measured on an ELISA plate 
reader (Thermo max Molecular Devices, St Gr ´egoire, France) at a wave- 
length of 490 nm. 
2.14. Cell cycle synchronisation and analysis 
Cells were seeded (3 × 10 6 cells) in a 25 cm 2 ﬂask and allowed to 
grow for 24 h. Synchronisation was then achieved using the method 
of Barascu et al. [ 35 ] and Bugler et al. [ 36 ] with slight modiﬁcations. 
Cells were serum-starved for 24 h in RPMI-1640 to produce a G0-G1 
cell cycle arrest, then the medium was replaced and cells were incu- 
bated in medium containing 2.5 mM thymidin for 16 h, and 300 μM 
hydroxyurea was added for another 24 h to accumulate the cells at the 
end of G1. Cells were extensively washed and cell cycle progression 
allowed once fresh medium containing 10% FCS has been added. Cells 
were harvested at various time points after being released (from 4 to 
60 h), ﬁxed in cold methanol and stored at −20 ◦C until analysis. After 
removal of methanol, cells were treated with the Coulter DNA-Prep 
reagents kit (Beckman Coulter, Villepinte, France) and analysed with 
a Coulter ® Epics XL-MCL TM ﬂow cytometer. Cell cycle distribution 
was determined with the Multicycle-AV software (Phoenix Flow Sys- 
tems, San Diego, CA) as previously described [ 35 ]. At the time points 
indicated, cells were also processed for cyclin expression analysis by 
immunoblotting. 
2.15. Apoptosis and caspase 3 and 7 activity in tumour cells and in vivo 
Apoptosis was evaluated in tumour cells using a monoclonal an- 
tibody against single-stranded DNA to quantitate the apoptotic cells 
after denaturation of DNA by heating in the presence of formamide. 
After washing twice with phosphate buffer saline 1 × (PBS), 1.5 ×
10 6 cells / ml were ﬁxed by methanol for 24 h at −20 ◦C, resuspended 
in formamide for 5 min at room temperature, heated for 10 min in 
a water bath at 75 ◦C and cooled for 15 min in an ice water bath. 
After centrifugation, cells were incubated with 10 μg / ml anti-ssDNA 
monoclonal antibody (Mab F7-F26 clone, AbCys, Paris, France) in PBS 
containing 5% FCS for 15 min at room temperature and rinsed with 
PBS. Cells were then exposed to ﬂuorescein-conjugated anti-mouse 
IgM (20 μg / ml in PBS containing 1% non-fat dried milk) for another 15 
min at room temperature and rinsed. Negative controls were treated 
with mouse IgM instead of the speciﬁc primary antibody. 
The activity of both caspase 3 and 7 was evaluated simultaneously 
using the ApoTox-Glo TM Triplex assay (Caspase-Glo ® 3 / 7 Substrate, 
Promega) together with cell viability (GF-AFC Substrate) and cell cy- 
totoxicity (bis-AAF-R110 Substrate). Cells were incubated for 24 h at 
37 ◦C. The substrates GF-AFC and bis-AAF-R110 were added and ﬂuo- 
rescence was measured (excitation 400 nm / emission 485 nm and 505 
nm / 520 nm, respectively) after 30 min incubation at 37 ◦C. Lumines- 
cence was detected after 30 min incubation with the Caspase-Glo ®
3 / 7 Substrate. 
Apoptosis in lung cancer cells was also evaluated in vivo after 
subcutaneous implantation of NCI-H209 cells expressing TFPI-2 or 
non-TFPI-2-expressing cells in nude mice as described above. Animals 
were sacriﬁced after 4 weeks and the apoptotic index was determined 
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Fig. 1. Immunohistochemistry analysis of small cell lung cancer samples (SCLC). (A) 
Immunostaining of neuroendocrine and epithelial differentiation markers, chromo- 
granin, synaptophysin, CD56 and KL1 on tissue sections from patients with SCLC. (B) 
Immunostaining of TFPI-2 using labelled streptavidin–biotin immunoenzymatic de- 
tection after incubation with a rabbit polyclonal antibody speciﬁc to human TFPI-2 and 
haematoxylin counterstaining. Representative samples with immunostaining intensity 
from 0 to 3. Original magniﬁcation ×40. (C) Immunostaining intensity of MMP-1, -2, -3 
and -9 according to low (intensity 0 and 1) or high level of TFPI-2 expression (intensity 
2 and 3) for each of the 40 tissue samples. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 together with cleaved caspase 3 immunostaining on formalin-ﬁxed,
parafﬁn-embedded tissue sections using automated BenchMarkXT
IHC / ISH staining (Roche) and Fidji software (ONIRIS, Nantes, France).
Five microscopic ﬁelds were analysed for each sample and the apop-
totic index was the positive stained area (pi 2 ) × 100 reported to total
nuclei (about 500 nuclei). Mitotic index is deﬁned as the number of
mitotic cells per ﬁeld observed at a magniﬁcation ×40. 
2.16. Statistical analysis 
Data were expressed as means ± SEM or median ± 1st quartile /
3rd quartile. Statistical analysis was carried out using the Student’s t
test (two tailed) or Mann Whitney test. A P -value below or equal to
0.05 was considered statistically signiﬁcant. 
3. Results 
3.1. TFPI-2 and MMP expression in human small cell lung cancer 
Biopsy specimens of SCLC obtained from 40 patients (30 men and
10 women) aged 45–84 years (median 65 years) were studied. Ninety-
seven percent of these patients were smokers. Twenty-ﬁve patients
(63%) had advanced disease with metastases at the time of diagnosis.
Only 2 of 36 patients for whom survival data were available were still
alive at the last follow up. The median overall survival was 6 months
and the 2-year survival rate was 5.5%. The diagnosis of SCLC was
made primarily on haematoxylin–eosin–safran stained slides show-
ing small malignant cells with high mitotic rates. Among the epithelial
markers (i.e. pan-cytokeratins (KL1) and epithelial membrane antigen
(EMA)) and neuroendocrine differentiation markers (i.e. CD56, chro-
mogranin A and synaptophysin) at least three of them were expressed
in all tumours ( Fig. 1 A). We then examined TFPI-2 and MMP-1, -2, -
3 and -9 expression in lung samples of 40 patients with SCLC and
established staining intensity from 0 to 3 by immunohistochemistry.
Homogeneous expression of TFPI-2 and MMP was observed in 100% of
tumour cells in lung samples. Low levels of TFPI-2 (staining intensity
of 0 or 1) were found in 26 (65%) SCLC specimens while high levels
of TFPI-2 expression were found in only 14 (35%) SCLC specimens,
including only 1 with a staining intensity of 3 ( Fig. 1 B). The highest
expression level in MMPs was found for MMP-1 with a staining in-
tensity of 2 for 50% of specimens ( Fig. 1 C). For MMP-2, MMP-3 and
MMP-9, an immunostaining intensity of 1 was predominant in 50%,
57.5% and 61.5% of biopsies, respectively. To determine the relation-
ship between TFPI-2 and MMPs, we compared the immunostaining
intensity obtained from the same tissue. In SCLC with low levels of
TFPI-2 (0 and 1), MMP staining was mainly equal to that of TFPI-2 or
was higher for MMP-1 in only 38% of tissue samples (intensity of 2). In
tissues with high levels of TFPI-2 (2 and 3), none had higher levels of
MMP staining than those for TFPI-2. Staining levels for MMP-1 were
mostly equal to those for TFPI-2, and staining levels lower than those
for TFPI-2 were obtained for MMP-2 in all specimens, whereas for
MMP-3 and MMP-9 they were lower in 85.7% and 57.1% of tissues,
respectively. 
3.2. Restoration of TFPI-2 expression in human small cell lung cancer 
cells 
To study the potential involvement of TFPI-2 in the aggressive-
ness of these lung carcinomas, NCI-H209 cells from a SCLC speci-
men, positive for all three neuroendocrin markers (chromogranin,
synaptophysin and CD56 ( Fig. 2 A)) were used. These cells were stably
transfected to express ﬁreﬂy luciferase and a clone was then pas-
saged twice subcutaneously in mice to enhance tumorogenicity. Cells
were then transfected with an empty vector to obtain the 852 control
clone or with a plasmid encoding TFPI-2, and the two clones ex-
pressing TFPI-2 (T6 and T28) were selected for further experiments.Maximum TFPI-2 level was achieved with the T6 clone as assessed by
qPCR ( Fig. 2 B), the TFPI-2 triplet at 32, 30, and 27 kDa being observed
from the extracellular matrix of cells by Western blotting ( Fig. 2 C) and
by immunohistochemistry staining ( Fig. 2 D). TFPI-2 protein was less
strongly expressed in the T28 clone than in the T6 clone although no
TFPI-2 was found in 852 cells. These cells exhibited a very low level
of TFPI-2 mRNA and a 2 | CT| of 7.75 was obtained when the relative
expression of TFPI-2 cDNA from 852 cells was compared to the ref-
erence cDNA. Moreover, TFPI-2 mRNA was increased 6,000-fold and
18,000-fold in the T28 and T6 clone respectively compared to 852
cells. 
3.3. Up-regulation of TFPI-2 reduced tumour progression in a nude 
mouse orthotopic model 
The impact of TFPI-2 on tumour progression was explored using
luciferase-expressing cells intrabronchially implanted in nude mice.
Tumour growth was followed by bioluminescence imaging performed
every 2 weeks. Of 60 mice, only one died immediately after surgery
and two others died of tumour progression. After 9 weeks, lung tu-
mours were obtained in 95% of mice, with slight tracheal biolumi-
nescence in a few animals (5%). In mice implanted with 852 control
cells, strong luciferase activity was observed in the lungs from the ﬁrst
measurement performed 3 weeks after implantation to 7 and 9 weeks
when the signal remained stable ( Fig. 3 A). In contrast, mice receiving
T6 cells expressing TFPI-2 showed a weak luciferase signal 3 weeks
after implantation. This luciferase activity then increased regularly
over the experiment but remained signiﬁcantly lower than in mice
receiving 852 cells during 7 weeks. Computed tomography scanning
(CT) was performed to document tumour location and volume. In
all animals, tumours were located in the lower and middle parts of
the lung ( Fig. 3 B) and a good correlation was demonstrated between
bioluminescence and tumour volume measured with CT ( r = 0.87).
Similar results were obtained by measuring lung tumour size with cal-
liper when mice were autopsied at 9 weeks. Histological sections of
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Fig. 2. Development of highly tumorigenic clones of NCI-H209 Luc cells from human 
SCLC expressing varying amounts of TFPI-2. (A) Immunostaining of the neuroendocrine 
differentiation markers, chromogranin, synaptophysin and CD56 (original magniﬁca- 
tion, ×40). (B) Relative quantiﬁcation of TFPI-2 transcript levels in NCI-H209 Luc cells 
stably transfected with an empty vector (852) or a plasmid encoding TFPI-2 (T28 and 
T6) using qRT-PCR. Results expressed in 2 | CT| ( β-actin used as control gene) are pre- 
sented as median ± 1st quartile / 3rd quartile from six independent mRNA extractions 
and qRT-PCR performed in triplicate. (C) TFPI-2 protein expression in ECM extract 
using a rabbit polyclonal antibody against TFPI-2 by immunoblotting. (D) Immunohis- 
tochemistry staining of TFPI-2 (original magniﬁcation, ×40). 
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Fig. 3. Longitudinal progression of SCLC in nude mice implanted with NCI-H209 ex- 
pressing TFPI-2 or not. (A) Cell suspension (2.5 × 10 6 852 or T6 cells) containing 10 
mM EDTA and 4 mg / mL Matrigel 
TM 
was implanted in the lung. Tumour progression 
was monitored from 3 to 9 weeks using bioluminescence and a mean of 5 min integra- 
tion was used for acquisition. Signal intensity was quantiﬁed as the sum of all photons 
detected from both ventral and dorsal positions within the region of interest. Results 
represent means ± SEM ( n = 30 animals per group). (B) Tomography scanning of lung 
tumours was performed to document tumour location and measurement. Axial trans- 
verse sections were obtained from 3 to 9 weeks and tumour volumes were calculated 
using the ellipsoid formula 4 / 3 π (W / 2 × H / 2 × L / 2). Each scanning image is repre- 
sentative of results obtained in 9 animals per group (mean ± SEM). (C) Histopathology 
examination (haematoxylin–eosin–saffron staining) was performed on lungs 9 weeks 
after cell implantation ﬁxed in 10% buffered formalin and embedded in parafﬁn: 5- μm 
thick sections (original magniﬁcation ×2 and ×40) were used for (D) immunostaining 
of TFPI-2, (original magniﬁcation ×40). Arrows indicate necrotic zones. ungs stained with HES showed dense tumours with well-delineated 
orders. The bronchioles were compressed and alveoli invaded and 
estroyed. Necrotic zones were present in the central region of the 
umours, particularly in mice implanted with 852 cells ( Fig. 3 C), and 
acrophages were seen in the peripheral region. No metastases were 
etected after 9 weeks. Immunostaining was also performed on lung 
umours at 9 weeks to verify the in vivo stability of TFPI-2 expression. 
s expected, TFPI-2 was highly expressed in lung tumours obtained 
ith cells expressing TFPI-2 ( Fig. 3 D). 
.4. TFPI-2 reduced tumour cell proliferation and blocked G1 / S phase 
ell cycle transition 
To establish whether TFPI-2 could modify the cell proliferation 
hat might inﬂuence tumour progression, a MTS assay on cells ex- 
ressing TFPI-2 and on cells not expressing TFPI-2 was performed 
very 3 days over a period of 2 weeks. The 3 clones had the same 
roliferation rate for 10 days ( Fig. 4 A). In contrast, we clearly demon- 
trated that TFPI-2 expression in T6 and T28 cells signiﬁcantly reduced 
roliferation (4-fold) from the 12th day compared to that of 852 cells. 
Cell cycle phase distribution was then monitored by ﬂow cytom- 
try analysis using propidium iodide ( Fig. 4 B). Although cells were 
erum starved and treated with thymidin and hydoxyurea, synchro- 
isation was not completely achieved but cells were mostly in the 
1 phase (70–80%). At the time of release the 852 cells were more 
ngaged in the cell cycle than cells expressing TFPI-2, as shown by the lowest percentages of cells in the G1 phase and the highest in the 
S phase. By 16 h a signiﬁcant blockade in G1 phase was found for T6 
and T28 cells (80%) compared to 852 control cells. 
Western blotting also showed a marked increase in cyclin- 
dependent kinase inhibitors p15 and p27 in clones expressing TFPI-2 
compared to the control 852 cell line ( Fig. 4 C). No difference in CDK4 
was seen between the 3 clones. 
3.5. TFPI-2 increased lung cancer cell apoptosis 
To explore further the mechanisms by which TFPI-2 is able to 
regulate tumour progression, we investigated whether viability, cy- 
totoxicity and particularly apoptosis were affected when this serine 
protease inhibitor was up-regulated. The three evaluations were per- 
formed in the same well for each clone. First, the live-cell protease 
Marion Lavergne et al. / FEBS Open Bio 3 (2013) 291–301 297 
Fig. 4. Impact of TFPI-2 expression on cell growth and cell cycle in NCI-H209 cells. (A) 
Proliferation of cells expressing TFPI-2 (T6 and T28 cells) or not (852 cells) was assessed 
by MTS assay every 3 days over 2 weeks. Results represent median and quartile (Q1 and 
Q3) from at least 4 independent experiments using Mann Whitney statistical analysis 
with * p < 0.05, ** p < 0.01, *** p < 0.001. (B) Cell cycle phase distribution of NCI-H209 
cells after serum starvation for 8 h, and exposure to 2.5 mM thymidine for 16 h and 
300 μM hydroxyurea for 24 h. After culture with medium containing 10% FCS for 0, 8, 
16 and 24 h, cells were stained with propidium iodide and analysed by ﬂow cytometry. 
The percentages of cells in G0 / G1, S, G2 / M phases are expressed as the median and 
quartiles of at least 3 independent experiments. (C) Representative immunobloting of 
p15, p27 and CDK4 involved in cell cycle and β-actin as the loading control, expressed 
in 852, T28 and T6 cells. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 5. Effects of TFPI-2 upregulation on cell viability, cytotoxicity and apoptosis. Via- 
bility (A) and cytotoxicity (B) of cells expressing TFPI-2 (T6 and T28) or not (852 cells) 
were simultaneously evaluated using two ﬂuorogenic substrates. Caspase 3 and 7 were 
evaluated by measuring activity following bioluminescent substrate cleavage (C) and 
by immunoblotting (D). (E) Apoptosis evaluation of 852, T28 and T6 cells by ﬂow cy- 
tometry using a monoclonal antibody against single-stranded DNA. Results represent 
median and quartiles (Q1 and Q3) from at least 4 independent experiments using Mann 
Whitney statistical analysis with * p < 0.05, ** p < 0.01, *** p < 0.001. (F) Apoptosis in 
852 and T6 lung cancer cells implanted in nude mice. After immunostaining on lung 
tissue samples using a cleaved caspase 3 antibody, apoptotic index was deﬁned as the 
ratio of positive tumour cells to total cells ( n = 500). Results were obtained in 9 animals 
per group (median and quartile (Q1 and Q3)). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 activity, measured using a ﬂuorogenic substrate cleaved into intact
cells, remained unchanged in the 852, T28 and T6 cells ( Fig. 5 A). In
contrast, cytotoxicity was signiﬁcantly higher in T6 cells expressing
TFPI-2, as demonstrated by the addition of a second ﬂuorogenic sub-
strate used simultaneously to measure dead-cell protease activity
released from cells that had lost membrane integrity ( Fig. 5 B). In the
second step, apoptosis was also evaluated in the three cell clones by
measuring the luminescence signal following caspase-3 / 7 substrate
cleavage. As shown in Fig. 5 C, a signiﬁcant increase in caspase 3 / 7
activity was found for T6 cells expressing TFPI-2 compared to 852
control cells. Similarly, an increase in cleaved caspase 3 was observed
by Western blotting in T28 and T6 cells compared to 852 cells ( Fig. 5 D).
Moreover, apoptotic cells were detected using a monoclonal antibody
that speciﬁcally recognised single-stranded DNA. An apoptosis level
of 15% was observed in 852 cells ( Fig. 5 E) and a signiﬁcant increase in
apoptotic cells related to the TFPI-2 level expressed in tumour cells
was observed. Indeed, more apoptotic cells were obtained with the
T6 clone, expressing the highest level of TFPI-2, compared to the T28clone. Finally, the higher rate of apoptosis in T6 cells was also found in
vivo . Tumours obtained after subcutaneous implantation of 852 and
T6 cells in nude mice for 4 weeks were harvested. After immunos-
taining for cleaved caspase 3 on sample sections, there was a trend
towards higher rate of apoptosis in the T6 cell tumours in-vivo ( Fig.
5 F). Moreover, a lower mitotic index was observed in mice receiving
T6 cells expressing TFPI-2 compared to 852 cells (i.e. 11 vs 23). 
3.6. Impact of TFPI-2 over-expression on matrix metalloproteinase 
expression in SCLC cells 
The proteases known to be affected by TFPI-2 expression are ma-
trix metalloproteinases which are involved in ECM degradation and
the spread of cancer cells. Levels of MMP-1, -2, -3 and -9 transcripts
were therefore quantiﬁed in 852, T28 and T6 cells using RT and qPCR
( Fig. 6 ). Varying amounts of MMP transcripts were quantiﬁed in all
cell clones, except MMP-2 mRNA which was not detected in any of
the cell clones studied. A low level of MMP-9 mRNA was expressed in
852 cells and the transcripts decreased in T28 ( p < 0.01) and T6 cells
( Fig. 6 A). However, gelatinolytic activity of proMMP-9 and proMMP-
2 was found in the conditioned medium of all clones, with a higher
signal for proMMP-2. Increased activity was obtained with T28 and
T6 clones expressing TFPI-2. In contrast, a decrease in MMP-1 mRNA
was found for the two clones expressing TFPI-2, but the difference
was signiﬁcant only for the T6 clone ( p < 0.001) compared to the 852
control clone ( Fig. 6 B). Similar results were obtained with MMP-3,
as mRNA levels were signiﬁcantly decreased ( p < 0.01) in T28 and
T6 cells (13-fold and 5-fold, respectively) ( Fig. 6 C). Western blotting
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Fig. 6. Impact of TFPI-2 on MMP expression in 852, T28 and T6 cells (A) Relative 
expression of MMP-9 transcripts normalised to β-actin transcripts using qRT-PCR. 
Gelatinase activity of MMP-2 and MMP-9 in 80-fold concentrated conditioned media 
from cells cultured for 4 days and analysed on gelatin zymography. (B) qRT-PCR for 
MMP-1 transcripts and representative Western blotting analysis of cell lysate proteins 
extracted from each clone using β-actin as the loading control. (C) qRT-PCR for MMP- 
3 transcripts and Western blotting analysis of cell lysate proteins. Data for relative 
quantiﬁcations of mRNA represent median and quartiles (Q1 and Q3) from at least 
4 independent experiments. Mann Whitney statistical analysis was used to compare 
results from 852 cells and cells expressing TFPI-2 (T28 and T6 cells) with * p < 0.05, ** p 
< 0.01, *** p < 0.001. Western blotting and gelatin zymography are representative of at 
least 4 independent experiments. 
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Fig. 7. TFPI-2 effects on phosphorylation state of proteins involved in MAPK signalling 
pathway. (A) Representative Western blotting of P-Raf, P-MEK, P-ERK, ERK, P-GSK-3 β
and β-actin as control with 852, T28 and T6 cell lysate extracts. (B) Densitometric 
analysis of immunoblots. The relative intensity of target protein is normalised to β- 
actin and then reported to 852 cell values. Data represent the median and quartiles Q1 
and Q3 of three immunoblots. Mann Whitney statistical analysis was used to compare 
results from 852 cells and cells expressing TFPI-2 (T28 and T6 cells) with * p < 0.05, ** p 
< 0.01, *** p < 0.001. 
 lso clearly showed that this decrease in MMP-1 and MMP-3 tran- 
cripts was associated with lower protein expression ( Fig. 6 B and C). 
he proform of MMP-1 at 52 kDa was observed, while MMP-3 was 
isualised as both pro and active forms in the 3 clones (54 and 44 kDa, 
espectively). 
.7. TFPI-2 inhibited phosphorylation of proteins involved in MAPK 
ignalling pathway 
To determine whether the MAPK signalling pathway which is in- 
olved in the induction of MMP synthesis was activated in TFPI-2-up- 
egulated small cell lung cancer cells, we investigated phosphoryla- 
ion of RAF, MEK1 / 2 and ERK1 / 2 proteins using immunoblotting. As 
hown in Fig. 7 , overexpression of TFPI-2 in T28 and T6 clones de- 
reased the level of P-RAF, P-MEK1 / 2 and P-ERK-2, but the difference 
as signiﬁcant only for one clone expressing TFPI-2. No difference 
as obtained in ERK-1 / 2 and P-ERK-1 between the three clones. In 
ontrast, serine-9 phosphorylation of GSK3 β was signiﬁcantly en- 
anced in T28 and T6 cells. No difference in protein loading was 
hown by β-actin immunodetection. 
. Discussion 
TFPI-2 is a tumour suppressor gene which is often downregulated 
n particularly aggressive tumours such as gliomas [ 9 , 37 ], melanomas 
 13 ], hepatocellular carcinomas [ 16 ] and non-small cell lung cancer 
 10 ]. However, documentation for SCLC, the most aggressive lung 
ancer, is poor due to the scarcity of specimens available to study the mechanisms of tumour progression. The originality of the study pre- 
sented here was the investigation of TFPI-2 expression in lung sam- 
ples from patients with SCLC. For the ﬁrst time we demonstrated low 
levels of expression of TFPI-2 in 65% of tumours, most patients being 
diagnosed at an advanced stage of the cancer. Indeed, extremely poor 
survival was observed, with a median overall survival of 6 months 
and a 2-year survival rate of 5.5%. Such TFPI-2 downregulation may 
be due to promoter methylation, as shown in various types of cancer 
[ 12 , 14 , 16 , 18 , 37 , 38 ] and particularly in patients with later stages of
NSCLC, as we have previously reported [ 10 ]. Moreover, in a previous 
study, poor prognosis was associated with TFPI-2 promoter methy- 
lation status in NSCLC [ 11 ], suggesting that the methylation of the 
TFPI-2 gene or TFPI-2 expression might be independent factors for 
poor survival or favourable outcome, respectively. However, the im- 
pact of TFPI-2 expression levels in SCLC cells that themselves exhibit 
low level of TFPI-2 has not yet been established. We therefore investi- 
gated whether the TFPI-2 restoration in the NCI-H209 cell line might 
have a beneﬁcial effect by regulating mechanisms involved in tumour 
progression. The NCI-H209 SCLC cell line was established from bone 
marrow metastases of a patient with histologically conﬁrmed small 
cell lung carcinoma [ 39 ]. These cells are small in size with scant cy- 
toplasm, and show the classic neuroendocrine features and markers 
of SCLC [ 40 ] and grow as packed ﬂoating cell aggregates, irregular 
in outline. Moreover, genome sequencing of NCI-H209 cells recently 
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detected in tumour cells. Some authors showed that MMP-2 located identiﬁed the combined loss of RB1 and TP53 typically observed in
SCLC, demonstrating that this cell line clearly represents this disease
[ 41 , 42 ]. Using this cell line, that we previously genetically modiﬁed
to express ﬁreﬂy luciferase, we developed a reproducible and reliable
nude mouse orthotopic model that resembles human SCLC [ 34 ]. The
growth of the primary tumour was sensitively and non-invasively
followed by bioluminescence imaging that allowed real-time moni-
toring of tumour progression in the same animals over a 2- to 9-week
period without sacriﬁcing animals at different tumour stages. Using
this original lung cancer model with cells transfected to overexpress
TFPI-2, our results demonstrated that TFPI-2 expression signiﬁcantly
inhibited lung tumour growth over 7 weeks after implantation com-
pared to tumour growth measured with cells expressing very low
levels of TFPI-2. With the latter cells we also observed necrotic zones
in the central region of the tumours, as frequently reported in hu-
man SCLC [ 40 ]. After 7 weeks, no signiﬁcant difference was found be-
tween tumours obtained with cells with or without TFPI-2 expression.
When necrosis was present, light emission generated by oxidation of
luciferase substrate was decreased due to ATP depletion, thus under-
estimating cancer cell counts. We therefore combined 2D biolumines-
cence and tomography scanning that clearly demonstrated that tu-
mour volume developed with cells not expressing TFPI-2 was greater
than when TFPI-2 was present. Few studies have been performed in
mice for other kinds of human cancers and these have shown that
TFPI-2 expression limits tumour progression. Indeed, restoration of
TFPI-2 expression in ﬁbrosarcoma cells after transfection with a plas-
mid encoding TFPI-2 has been reported to reduce subcutaneous tu-
mour growth [ 43 ] and similar results were obtained in an orthotopic
pancreatic carcinoma model [ 33 ]. 
Several mechanisms are involved in tumour progression, including
cell proliferation and apoptosis, cell migration and invasion requiring
degradation of the extracellular matrix by a variety of proteinases
such as metalloproteinases. A decrease in cancer cell proliferation af-
ter TFPI-2 expression has also been reported in pancreatic carcinoma
cells [ 15 , 33 ], oesophageal and nasopharyngeal cancer cells [ 18 ], gall-
blader carcinoma cells [ 44 ], glioma cells [ 45 ] and choriocarcinoma
cells [ 46 ]. Nevertheless, this effect may be tumour-speciﬁc, as some
authors have attributed no antiproliferative effect to TFPI-2 [ 29 , 32 ].
Indeed, in contrast to NSCLC where TFPI-2 did not impact cell on pro-
liferation [ 27 ], we showed in our study that TFPI-2 reduced the cell
proliferation rate, with a low overall number of cells expressing TFPI-
2. We also demonstrated for the ﬁrst time in SCLC that TFPI-2 blocks
the G1 / S transition phase of the cell cycle, associated with an increase
in the cyclin-dependent kinase inhibitors p15 and p27. The involve-
ment of p27 (that blocks G1 / S-transition by regulating CDK2 [ 47 ]) in
cell cycle dysregulation has been reported by several authors [ 48 , 49 ]
in NSCLC as well as in other cancers such as prostate cancer [ 50 ] and
ﬁbrosarcoma [ 51 ]. Moreover, transduction of NSCLC cells with an ade-
novirus expressing p27 was found to result in G1 / S arrest and induce
suppression of xenograft lung tumour growth in nude mice [ 52 ]. Low
levels of p27 in lung cancer have also been reported to be associated
with poor prognosis [ 53 , 54 ], and a better survival rate was reported
in NSCLC when p27 expression was high [ 55 ]. However, these ﬁnd-
ings are controversial [ 56 ] and could be explained by a dual effect
of p27 depending on its nuclear sequestration, thus becoming non-
functional in inhibiting cell cycle progression. We also showed that
the p15 cell cycle regulator which increased in cells expressing TFPI-2
might also be involved in the inhibition of proliferation observed in
these cells. Indeed, increases in p15 and p27 expression were also
obtained concomitantly with inhibition of proliferation and induc-
tion of arrest of the G1 phase cell-cycle in a A549 lung cancer cell line
treated with a derivative of genistein [ 57 ]. Interestingly, genistein has
been reported to induce TFPI-2 and to inhibit growth and metastasis
of breast cancer cells [ 58 ]. Although the p15 gene promoter was less
frequently deleted or aberrantly methylated in lung cancers than in
other cancers [ 59 , 60 ], the overall survival of patients with promotermethylation was shortened in NSCLC [ 61 ]. 
In parallel of the limited proliferation of lung cancer cells express-
ing TFPI-2, we also demonstrated induction of apoptosis in these cells
via an increase in caspase 3 activity both in vitro and in vivo . These
ﬁndings are in agreement with previous studies demonstrating the
pro-apoptotic activity of TFPI-2. TFPI-2 is thus able to induce death
receptor-mediated apoptosis through increases in FasL, TNF- α, and
death domains FADD and TRADD. It also induces apoptosis through
the mitochondrial-dependent caspase cascade, with upregulation of
pro-apoptotic Bax, cleaved Caspase 3 and 9, released cytochrom c
and Apaf-1 and a decrease in anti-apoptotic Bcl2 [ 31 , 62 , 63 ]. More-
over, we have shown here that TFPI-2 could also regulate apopto-
sis by inhibiting GSK-3 β (glycogen synthase kinase-3 β) activity via
Ser-9 phosphorylation, as observed in SCLC cells expressing TFPI-2.
GSK-3 β is involved in both glycogen metabolism and cell signalling
and can regulate cell cycle progression and apoptosis, with conse-
quently pro or anti tumour activity [ 64 ]. Indeed, GSK-3 β activity is
enhanced by phosphorylation of tyrosine 216 and inhibited by phos-
phorylation of serine 9. It has been shown that GSK3 inhibition can
decrease viability and induce apoptosis in colon cancer cells [ 65 ],
glioma cells [ 66 ], and pancreatic cancer cells [ 67 ]. Moreover, GSK-3
inhibition suppresses NF- κB, downregulates anti-apoptotic protein
Bcl2 and induces cleaved caspase-3 following exposure of pancreatic
cancer cells to TRAIL [ 68 ]. In the present study, we also showed with
a subcutaneous xenograft model that more apoptotic cells and fewer
cells undergoing mitosis were observed in tumours developed with
cells expressing TFPI-2. Similar results have also been reported in
mice that received ﬁbrosarcoma cells expressing TFPI-2, with higher
percentages of cells undergoing apoptosis in the core cell region of
tumours [ 43 ]. 
Cell invasion and tumour progression also require degradation of
the extracellular matrix by several proteinases, particularly metallo-
proteinases. Several authors have described TFPI-2 as an inhibitor of
MMP activity directly or mainly for MMP-1, -2, -3 and -9 via plas-
min inhibition [ 32 , 69 , 70 ]. In addition to these direct mechanisms of
inhibition, our in vitro ﬁndings demonstrated a decrease in MMP-1
and MMP-3 transcripts and proteins in SCLC cells expressing TFPI-2
that could also explain the inhibition of tumour growth observed in
mice. In accordance with our previous study, when TFPI-2 expression
was silenced in NSCLC cells, we observed increases in MMP-1 and
MMP-3 transcript levels and proteins [ 27 ]. These ﬁndings therefore
suggest that TFPI-2 may regulate MMP mRNA expression like a tran-
scription factor and this could be due to its carboxy-terminal tail that
is internalised into cells and translocated into the nucleus [ 71 ]. On
the other hand, the decreases in MMP-1 and -3 may be explained
by downregulation of the mitogen-activated protein kinase (MAPK)
pathway involving Ras / Raf / MAPK / extracellular signal-regulated ki-
nase (ERK), as observed in glioma cells [ 72 ]. Indeed, we demonstrated
in the present study that cells expressing TFPI-2 tend to reduce phos-
phorylation of Raf and MEK that are known to be involved in the
activation of many MMP [ 73 ]. Moreover, the down-regulation of the
ERK signalling pathway has been reported to be involved in the inhi-
bition of lung tumour cell invasion [ 74 ]. Surprisingly, MMP-2, -3 and
-9 were slightly expressed in lung samples without relationship with
high or low levels of TFPI-2. The low level of MMP-2 and MMP-9 de-
tected in human SCLC tissues could explain that conditioned media
need to be concentrated about 80-fold to detect these pro-MMP in
852 cells. In fact, we previously observed in TFPI-2 silenced NCI-H460
a decrease in MMP-2 mRNA that was inversely correlated to MMP-1
and -3 expression [ 27 ]. Moreover when MMP-2 and -9 mRNA was as-
sessed in tumour and non-affected tissues from patients with NSCLC,
we showed a similar level of MMP-2 mRNA in both tissues whereas
MMP-1, -3 and -9 mRNA were signiﬁcantly higher in tumours ([ 25 ]
and personal data). This could be explained by a difference in locali-
sation of MMP-2 detected in stromal cells while MMP-9 was mainly
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 n stromal cells rather than in tumour cells plays a signiﬁcant role in 
he prognosis of NSCLC [ 75 ]. In contrast, we found that MMP-1 was 
redominant in SCLC tissues. Moreover, TFPI-2 expression was the in- 
erse of MMP-1 in 35% of cases and thus was in accordance with our in 
itro studies. Because surgical specimens of SCLC are scarce, our study 
as performed mainly on small samples obtained by bronchial en- 
oscopy or mediastinoscopy, thus allowing only immunohistochem- 
stry analyses. The impact of TFPI-2 on MMP expression remains to 
e further explored within other SCLC tissues. 
In conclusion, the study we report provides evidence that TFPI-2 
an inhibit SCLC tumour progression by inhibiting cell proliferation 
ainly by the induction of apoptosis and also arresting the transition 
hase G1 / S cell cycle. Moreover, TFPI-2 might limit tumour invasion 
y a mechanism dependent on regulation of MMP-1 and -3 and the 
RK signalling pathway. The frequent downregulation of TFPI-2 in 
CLC probably contributes to the aggressive nature of this lung cancer. 
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